

References

- Van Dyke RA, Chenoweth MB, Von Poznak A: The metabolism of volatile anesthetics. I. Biochem Pharmacol 13:1239-1247, 1964
- Van Dyke RA: The metabolism of volatile anesthetics. III. J Pharmacol Exp Ther 154: 364-369, 1966
- Rehder K, Forbes J, Alter H, et al.: Halothane biotransformation in man. ANESTHESIOLOGY 28:711-715, 1967
- Casorbi MF, Blake DA, Helrich M: Differences in the biotransformation of halothane in man. ANESTHESIOLOGY 32:119-123, 1970
- Holiday DA, Rudofsky S, Treuhaft PS: Metabolic degradation of methoxyflurane in man. ANESTHESIOLOGY 33:579-593, 1970
- Van Dyke RA, Chenoweth MB: The metabolism of volatile anesthetics. II. Biochem Pharmacol 14:603-609, 1965
- Van Dyke RA, Chenoweth MB: The metabolism of volatile anesthetics. ANESTHESIOLOGY 26:348-357, 1965
- Airaksinen MM, Tammisto T: Toxic actions of the metabolites of halothane. Ann Med Exp Biol Fenn 46:242-248, 1968
- Airaksinen MM, Rosenberg PM, Tammisto T: A possible mechanism of toxicity of trifluoroethanol and other halothane metabolites. Acta Pharmacol Toxicol 28:299-304, 1970
- Taves PR, Foy BW, Freeman RB, et al.: Toxicity following methoxyflurane anesthesia. II. JAMA 214:91-95, 1970
- Hodge MC, Smith FA: Fluorine Chemistry. Volume IV. Edited by JH Simons. New York, Academic Press, 1965
- Fluorides and Human Health: World Health Organization. Monograph no. 59, 1970
- Sawyer DC, Eger EI II, Bahlman SH, et al.: Concentration dependence of hepatic halothane metabolism. ANESTHESIOLOGY 34: 230-235, 1971
- Sawyer DC, Eger EI II, Bahlman SH, et al.: Metabolism of inhalation anesthetics. Conference on Cellular Toxicity of Anesthetics, Seattle, 1970
- Eger EI II, Saidman LJ, Brandstater B: Minimum alveolar anesthetic concentration: A standard of anesthetic potency. ANESTHESIOLOGY 26:756-763, 1965
- Larson CP Jr, Eger EI II, Severinghaus JW: The solubility of halothane in blood and tissue homogenates. ANESTHESIOLOGY 23: 349-355, 1962
- Eger EI II, Sharpl R: The solubility of methoxyflurane in human blood and tissue homogenates. ANESTHESIOLOGY 24:625-627, 1963
- Gregory GA, Eger EI II: Partition coefficients in blood and blood fractions at various concentrations of cyclopropane. Fed Proc 27: 705, 1968
- Saidman LJ, Eger EI II, Munson ES, et al.: Minimum alveolar concentrations of methoxyflurane, halothane, ether and cyclopropane in man. ANESTHESIOLOGY 28:994-1002, 1967
- Gregory GA, Eger EI II, Munson ES: The relationship between age and halothane requirement in man. ANESTHESIOLOGY 30: 488-491, 1969
- Berman ML, Bochartin JF: Enzyme induction by preservatives in volatile anesthetics. Conference on Cellular Toxicity of Anesthetics, Seattle, 1970
- Cohen EN: Metabolism of halothane-2 ¹⁴C in the mouse. ANESTHESIOLOGY 31:560-565, 1969
- Mazze R, Shakespeare T: Private communication, 1970
- Scholler KL: Modification of the effects of chloroform on the rat liver. Brit J Anaesth 42:603-605, 1970
- Scholler KL, Müller E, von Plehwe U: Verstärkung und unterdrückung der Toxizität von Chloroform für die Leber durch Pharmaka. Arzneimittel-Forschung (Drug Research) 20:289-292, 1970

Drugs

TOXICITY OF AEROSOLS The fluoroalkane gases used to propel aerosols were toxic to the hearts of 34 mice, sensitizing them to sinus bradycardia, atrioventricular block, and T-wave depression induced by asphyxia. Cardiac sensitization was rapid, long-lasting, and lethal. It also occurred in rats and dogs. The propellants are postulated to possess a spectrum of cardiotoxic effects capable of causing bradyarrhythmias, tachyarrhythmias, or myocardial depression. In humans the cardiac toxicity of aerosol propellants, particularly during asphyxia, may be a cause of sudden death in youths who "turn on" by inhaling propellants and in patients with asthma who use bronchodilator aerosols excessively. Cardiac toxicity due to propellant inhalation may be a potential hazard to frequent users of pressurized aerosol dispensers. (Taylor, G. J., and Harris, W. S.: *Cardiac Toxicity of Aerosol Propellants*, J.A.M.A. 214: 81 (Oct.) 1970.)